Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference

Company to Review Milestones for its Phase 2b Study of FX-322, the Near-Term Clinical Plan for its Second Hearing Restoration Asset, FX-345, and Selection of a Lead Candidate for its Novel Multiple Sclerosis Program that Has Shown Potent Pre-Clinical Data

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that Chief Executive Officer David L. Lucchino will present a Company overview at the 40th Annual J.P. Morgan Healthcare Conference.

Mr. Lucchino’s presentation will take place on January 13^th at 10:30 a.m. ET and will be followed by a question-and-answer session immediately thereafter. A live webcast of both the presentation and the breakout session can be accessed on the investors section of Frequency’s website, investors.frequencytx.com. A replay of the presentation will be posted on the Frequency website following the event.

About Frequency Therapeutics

Frequency Therapeutics is leading a new category in regenerative medicine that aims to restore function – first in hearing loss and then in multiple sclerosis (MS) – by developing therapeutics that activate a person’s innate regenerative potential within the body through the activation of progenitor cells to restore lost function. Frequency’s hearing research focuses on cochlear restoration and auditory repair, and its lead asset, FX-322, is a small-molecule product candidate that is the first to show statistically significant and clinically meaningful hearing improvements in clinical trials for SNHL. Frequency is also following early restorative signals in MS to develop medicines with the same underlying regenerative science being brought to hearing loss.

Headquartered in Lexington, Mass., Frequency has an ex-U.S. license and collaboration agreement with Astellas Pharma Inc. for FX-322, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, the Scripps Research Institute and Cambridge Enterprises Limited. For more information, visit www.frequencytx.com and follow Frequency on Twitter @Frequencytx.